IGC Pharma (IGC) EBITDA Margin (2010 - 2025)
IGC Pharma (IGC) reported EBITDA Margin of 963.35% for Q3 2025, down 54296.0% year-over-year from N/an in Q3 2024, and down 97.24% quarter-over-quarter from 488.41% in Q2 2025.
IGC Pharma (IGC) EBITDA Margin (2010 - 2025) Analysis & Trends
IGC Pharma (IGC) has 16 years of EBITDA Margin data on file, last reported at 963.35% in Q3 2025.
- EBITDA Margin for Q3 2025 came in at 963.35%, down 54296.0% year-over-year; the trailing twelve-month figure through Sep 2025 was 585.99% (up 47631.0% YoY), and the FY2026 annual result was 760.25%, down 19762.0% from the prior year.
- EBITDA Margin eased to 963.35% in Q3 2025 per IGC's latest filing, from 488.41% in the prior quarter.
- Over five years, EBITDA Margin peaked at 361.21% in Q1 2025 and troughed at 7721.43% in Q3 2021.
- A 5-year average of 1871.72% and a median of 977.29% in 2024 frame the typical range for EBITDA Margin.
- On a YoY basis, EBITDA Margin climbed as much as 808621 bps in 2021 and fell as far as 650943 bps in 2021.
- A 5-year view of EBITDA Margin shows it stood at 1622.54% in 2021, then soared by 57 bps to 695.78% in 2022, then tumbled by 292 bps to 2730.88% in 2023, then jumped by 74 bps to 718.68% in 2024, then plunged by 34 bps to 963.35% in 2025.
- Business Quant data shows IGC's EBITDA Margin at 963.35% in Q3 2025, 488.41% in Q2 2025, and 361.21% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | IGC Pharma | 29.33 Mn | 29.07 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -963.35% |
| Jun 30, 2025 | -488.41% |
| Mar 31, 2025 | -361.21% |
| Dec 31, 2024 | -718.68% |
| Sep 30, 2024 | -420.39% |
| Jun 30, 2024 | -875.37% |
| Mar 31, 2024 | -977.29% |
| Dec 31, 2023 | -2,730.88% |
| Sep 30, 2023 | -863.92% |
| Jun 30, 2023 | -372.25% |
| Mar 31, 2023 | -2,403.01% |
| Dec 31, 2022 | -695.78% |
| Sep 30, 2022 | -1,299.01% |
| Jun 30, 2022 | -1,416.98% |
| Mar 31, 2022 | -5,498.36% |
| Dec 31, 2021 | -1,622.54% |
| Sep 30, 2021 | -7,721.43% |
| Jun 30, 2021 | -2,433.77% |
| Mar 31, 2021 | -3,700.00% |
| Dec 31, 2020 | -2,113.89% |